Patent ID: 8481497

Claim:
A composition for treatment of hepatic cancer, gallbladder cancer, colon cancer, stomach cancer, breast cancer, pancreas cancer, myeloma, or leukemia, comprising a fibroblast growth factor receptor-1 (FGFR-1) expression enhancer which is interferon-alpha, interferon-beta, or 5-azacitidine and an anti-FGFR-1 antibody or a fragment thereof that binds to FGFR-1, wherein the dosage of interferon-alpha is 5,000,000-10,000,000 units, the dosage of interferon-beta is 3,000,000-6,000,000 units, the dosage of 5-azacitidine is 0.01-10 mg/kg and the dosage of said antibodies is 100-200 mg.